Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

RARE

Ultragenyx Pharmaceutical Inc.

Pharmaceutical Preparations · SIC 2834CIK 1515673Held by 4 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$673.0M
Net Income FY2025
$(575.0M)
EPS (Basic, as reported)
$-5.83
Net Margin FY2025
-85.4%
ROE FY2025
718.8%
Total Equity
$(80.0M)
Shares Out
99M
Business description

Ultragenyx Pharmaceutical Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2012–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 0 → 673
Fiscal yearFY2016FY2017FY2018FY2019⚑FY2020FY2021FY2022FY2023FY2024FY2025
Revenue0351104271351363434560673
Cost of revenue—0(1)———————
Research & development(183)(232)(294)(357)(412)(497)(706)(648)(698)(750)
Selling, general & administrative(65)(100)(128)(162)(183)(220)(278)(310)(322)(349)
General & administrative(65)—————————
Total operating expenses(248)(332)(423)(528)(601)—————
Operating income(248)(329)(371)(424)(330)(382)(649)(569)(536)(535)
Interest & investment income4410137211273725
Other income (expense), net27(6)(1)1(2)(2)0(4)1
Pre-tax income(246)(318)(197)(399)(185)(453)(702)(608)(568)(571)
Income tax expense0(16)(1)(3)(1)(1)(6)(2)(2)(4)
Net income(246)(302)(198)(403)(187)(454)(707)(607)(569)(575)
EPS — basic————($3.07)($6.70)($10.12)($8.25)($6.29)($5.83)
EPS — diluted————($3.07)($6.70)($10.12)($8.25)($6.29)($5.83)
Shares outstanding — basic (M)————616870749199
Shares outstanding — diluted (M)————616870749199

Showing the latest 10 of 14 fiscal years.

  • ⚑ Weighted-average shares changed ×1.65 between FY2015 and FY2020 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.